Perma Fix Environmental Services Inc (PESI) · Nov 5, 2026 · Earnings
Beat — Revenue $17.9M vs ~$14.9M consensus; EPS -$0.16 vs -$0.21 consensus
Perma-Fix earnings beat Q3 revenue and EPS estimates, but treatment margins plunged and recurring losses keep the turnaround fragile.
Perma-Fix is trying to turn a government-driven Hanford/DFLAW ramp, a growing waste-treatment backlog and expanding PFAS destruction capacity into a recovery after a weak first half. The prior quarter already pointed to second-half improvement, with Hanford waste receipts beginning and treatment backlog rising, but it also carried a going-concern warning and heavy operating losses.
The quarter beat the published benchmark, but mostly because the bar was low. Revenue of $17.9 million exceeded the roughly $14.9 million consensus, while basic EPS of negative $0.16 was better than the approximately negative $0.21 estimate. That makes this an earnings beat, but not a clean operating win: revenue was only modestly above the prior-year quarter, and the company remained deeply loss-making.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Net revenue (Income Statement) | $17.9M (+2.8%) | $17.5M | ~$14.9M |
| Gross profit (Income Statement) | $0.6M (-78.4%) | $2.6M | |
| Operating loss (Income Statement) | $3.7M | $1.9M | |
| Net loss per share (Income Statement) | $(0.16) | $(0.10) | ~$(0.21) |
The core Treatment business is still the weak link. Treatment revenue fell to $11.6 million from $13.1 million, and the segment produced a $225,000 gross loss versus $2.3 million of gross profit a year earlier. Customer-directed Hanford protocol changes delayed processing, but the filing also says lower volumes and higher fixed costs hurt margins, meaning the recovery still depends on converting backlog and shipments into enough throughput.
Services is providing a genuine second engine. Services revenue rose 46% year over year, margin reached 12.2%, and the segment generated operating income. That improvement partially offsets the Treatment deterioration, while the $19.6 million Treatment backlog, price increases and rising DFLAW volumes give the turnaround a more tangible base than it had after Q2. 〔0〕
Liquidity remains the constraint on the recovery story. The company still disclosed substantial doubt about its ability to continue as a going concern despite roughly $19.9 million of PNC liquidity, because operating losses and cash needs remain dependent on government-directed shipments and project timing. The balance-sheet runway improved from the first half, but the filing does not remove the financing and execution risk that was already central to the story. 〔1〕
Bottom line: This was a narrow earnings beat and a sequential improvement, but the main Treatment business remains unprofitable. The event advances the recovery narrative only modestly; it does not yet prove that the Hanford backlog can produce durable positive earnings or eliminate the liquidity concern.
Gen 2.0 PFAS unit commissioning, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!